Human Papilloma Virus Infection
Conditions
Brief summary
Human papillomavirus (HPV) causes the most prevalent sexually transmitted infections in the world. The nonavalent HPV vaccine (9vHPV) provides protection against 9 high-risk HPV serotypes, responsible for causing approximately 90% of cervical and other HPV-related anogenital cancers, as well as 90% of genital warts. The risk of cancer is substantially increased among immunocompromised patients. Although studies have demonstrated seroprotection among children and adolescents, boys and girls, with the 9vHPV vaccine, the immunogenicity of this vaccine has been poorly explored in immunocompromised children and adolescents (including transplant patients, and those infected with human immunodeficiency virus (HIV)). Several factors, including the immunological consequences of vertically acquired infection, immunosuppressive therapies and age, could lead to an increased risk of infection in children and adolescents who are immunocompromised. Lower immunogenicity in these populations. These children may have a poor response to vaccines and therefore require additional doses. Markers such as CD4/CD8 or torque teno virus (TTV) replication could be linked to immunogenicity and thus serve as predictors of efficacy for routine clinical practice.
Interventions
BIOLOGICAL9-valent HPV vaccine
All participants will receive the immunization schedule according to guidelines: immunosuppressed patients will receive a three-dose schedule: 0.5 mL intramuscular injection of 9vHPV at entry plus an additional dose at month 2 and month 6. Healthy controls aged 9-14 years will receive a two-dose schedule: 0 and 6 months.
Sponsors
Talia Sainz Costa
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Intervention model description
Two groups of patients: Immunosuppressed Group: N=90 Immunosuppressed patients, consisting of HIV-infected children and adolescents, hematopoietic stem cell transplant (HSCT) recipients, solid organ transplant (SOT) recipients and post-chemotherapy patients (PCT) under follow-up at Hospital La Paz in Madrid Spain. Control Group: N=30 Healthy controls aged 9-14. Both groups receive the 9-valent HPV vaccine.
Eligibility
Sex/Gender
ALL
Age
9 Years to 18 Years
Healthy volunteers
Yes
Inclusion criteria
* Children or adolescents 9 to \<18 years of age * Willing to sign consent/assent form * If HIV positive, under ART and undetectable viral load and CD4 cell count \>200/mm3 (at least 6 months) * If the patient has received chemotherapy or is a SOT/HSCT recipient, referred for immunizations after adequate immune reconstitution according to routine clinical practice
Exclusion criteria
* Previous history of warts and/or anal cancer. * Previous immunization with any HPV vaccine. * Age below 9. * Patients who for any reason should not be included in the study according to the evaluation of the research team.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Seroconversion of subjects from baseline to month 7 (determined by serum anti-HPV antibody titers) | From baseline to month 7 | Percentage of subjects seroconverting from baseline to month 7 |
| Seroconversion of subjects from baseline to month 12 (determined by serum anti-HPV antibody titers) | From baseline to month 12 | Percentage of subjects maintaining antibody titers 12 months after immunization. |
| Seroconversion of subjects from baseline to month 18 (determined by serum anti-HPV antibody titers) | From baseline to month 18 | Percentage of subjects maintaining antibody titers 18 months after immunization. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ratio of geometric mean serum antibody titers (GMTs) | From baseline to month 7 | GMTs from baseline to month 7 |
| Delta of geometric mean serum antibody titers | From 1 to 12 months | Delta of geometric mean serum antibody titers from 1 to 12 months after immunization. |
| Percentage of subjects seroconverting from baseline to month 7 | From baseline to month 7 | Percentage of subjects seroconverting from baseline to month 7 in each of the study populations. |
Countries
Spain
Contacts
Primary ContactTalia Saínz Costa
Outcome results
None listed